BIOPHARMA
ByDid Metabolic Therapy Approvals in 2025 Reset the Standard of Care—and Ignite a New Growth Cycle in 2026?
Global – December 2025 — The metabolic therapeutic area emerged as one of the most transformative forces in…
Did Renal Therapy Approvals in 2025 Redefine Kidney Disease Management—and Set the Stage for Breakthroughs in 2026?
Global – December 2025 — The renal therapeutic area emerged as a renewed focus of innovation in 2025,…
Did Cardiovascular Approvals in 2025 Signal a New Era in Heart Disease Management—and Set the Pace for 2026 Innovation?
Global – December 2025 — The cardiovascular (CV) therapeutic area re-emerged as a strategic growth engine in 2025,…
Did Infectious Disease Approvals in 2025 Redefine Global Preparedness—and Set the Course for Innovation in 2026?
Global – December 2025 — The infectious diseases (ID) landscape underwent a structural recalibration in 2025, shaped by…
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at JPM2026 a Bet on the Next Wave of Immuno-Oncology?
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with a major oncology…
